Sofosbuvir Has Come Out of the Magic Box

After the introduction of hepatitis b (hbv) vaccination, which leaded to a dramatically decrease of hbv prevalence in the communities (1), it is predicted that hepatitis c virus (hcv) will emerge as the most common chronic viral liver disease in the next decades (2, 3). the global prevalence of hcv is at least 3% with over 170 million infected cases (4). the treatment regimens for chronic hepatitis c (chc) have progressed within the past decade. the current standard of care in our country consisting of pegylated interferon alpha (pegifnα) and ribavirin (rbv), has significantly improved the sustained virological response (svr) rates from 50% up to 80% in patients infected with different hcv genotypes.